Development of angiotensin II type 1 receptor antibodies in patients with temporary mechanical circulatory support
Maria T. Gamero, MD,
Mark Liotta, MD,
Yevgeniy Brailovsky, DO,
Gregory Gibson, MD,
Rene Alvarez, MD,
Patricia Uber, PharmD,
Yanping Huang, MD,
Indranee Rajapreyar, MD
Affiliations
Maria T. Gamero, MD
Department of Medicine, Division of Cardiovascular Disease, Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania; Corresponding author: Maria T. Gamero, MD, Department of Medicine, Division of Cardiovascular Disease, Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, PA.
Mark Liotta, MD
Department of Medicine, Division of Cardiovascular Disease, Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Yevgeniy Brailovsky, DO
Department of Medicine, Division of Cardiovascular Disease, Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Gregory Gibson, MD
Department of Medicine, Division of Cardiovascular Disease, Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Rene Alvarez, MD
Department of Medicine, Division of Cardiovascular Disease, Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Patricia Uber, PharmD
Department of Medicine, Division of Cardiovascular Disease, Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Yanping Huang, MD
Department of Pathology and Genomic Medicine, Jefferson University Hospital, Philadelphia, Pennsylvania
Indranee Rajapreyar, MD
Department of Medicine, Division of Cardiovascular Disease, Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania; Corresponding author: Maria T. Gamero, MD, Department of Medicine, Division of Cardiovascular Disease, Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, PA.
Angiotensin II type 1 receptor antibodies (AT1R-Ab) are among the most investigated type of non-human leukocyte antigen antibodies in solid organ transplantation, particularly given its association with allograft dysfunction. Some prior studies have described the development of AT1R antibodies in patients with durable mechanical circulatory support (MCS); however, the role of temporary MCS in autoantibody development is still uncertain. Given that the current United Network For Organ Sharing (UNOS) allocation system prioritizes heart transplant recipients in cardiogenic shock requiring temporary MCS, we investigated the development of these antibodies in 10 patients with temporary MCS (Impella 5.5 n = 8, Intra-aortic balloon pump n = 2) listed for heart transplant. We found that 7 out of 8 (87.5%) patients supported with Impella developed AT1R-Ab, while the remaining 1 patient was borderline positive. Two patients supported with an intra-aortic balloon pump did not develop AT1R-Ab. We attribute this difference to the endothelial shear stress imparted by Impella devices, although more investigation is needed.